EP3847191A4 - Récepteurs d'antigènes chimériques conditionnellement actifs pour lymphocytes t modifiés - Google Patents

Récepteurs d'antigènes chimériques conditionnellement actifs pour lymphocytes t modifiés Download PDF

Info

Publication number
EP3847191A4
EP3847191A4 EP19856976.6A EP19856976A EP3847191A4 EP 3847191 A4 EP3847191 A4 EP 3847191A4 EP 19856976 A EP19856976 A EP 19856976A EP 3847191 A4 EP3847191 A4 EP 3847191A4
Authority
EP
European Patent Office
Prior art keywords
chemera
lymphocytes
modified
antigen receptors
conditionally active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19856976.6A
Other languages
German (de)
English (en)
Other versions
EP3847191A2 (fr
Inventor
Jay M. Short
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioatla Inc
Original Assignee
Bioatla Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/125,302 external-priority patent/US11111288B2/en
Application filed by Bioatla Inc filed Critical Bioatla Inc
Publication of EP3847191A2 publication Critical patent/EP3847191A2/fr
Publication of EP3847191A4 publication Critical patent/EP3847191A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4251—Kinases, e.g. Raf or Src
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19856976.6A 2018-09-07 2019-08-23 Récepteurs d'antigènes chimériques conditionnellement actifs pour lymphocytes t modifiés Withdrawn EP3847191A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/125,302 US11111288B2 (en) 2014-08-28 2018-09-07 Conditionally active chimeric antigen receptors for modified t-cells
PCT/US2019/047848 WO2020050993A2 (fr) 2018-09-07 2019-08-23 Récepteurs d'antigènes chimériques conditionnellement actifs pour lymphocytes t modifiés

Publications (2)

Publication Number Publication Date
EP3847191A2 EP3847191A2 (fr) 2021-07-14
EP3847191A4 true EP3847191A4 (fr) 2022-06-08

Family

ID=69721682

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19856976.6A Withdrawn EP3847191A4 (fr) 2018-09-07 2019-08-23 Récepteurs d'antigènes chimériques conditionnellement actifs pour lymphocytes t modifiés

Country Status (6)

Country Link
EP (1) EP3847191A4 (fr)
JP (1) JP7432250B2 (fr)
CN (1) CN112823166B (fr)
AU (1) AU2019334864B2 (fr)
TW (1) TWI835848B (fr)
WO (1) WO2020050993A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230203168A1 (en) * 2020-06-02 2023-06-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual EGFR-MUC1 Chimeric Antigen Receptor T Cells
WO2022187182A1 (fr) * 2021-03-02 2022-09-09 The Trustees Of The University Of Pennsylvania Ciblage de lymphocytes t régulateurs vers des cellules d'îlots pour freiner ou inverser le diabète de type 1
CN115368470A (zh) * 2021-05-21 2022-11-22 南京卡提医学科技有限公司 靶向b7-h3的嵌合受体及其用途
CN115477704B (zh) * 2021-06-16 2024-02-23 四川大学华西医院 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033331A1 (fr) * 2014-08-28 2016-03-03 Bioatla, Llc Récepteurs d'antigènes chimères conditionnellement actifs pour cellules t modifiées
WO2018136570A1 (fr) * 2017-01-18 2018-07-26 F1 Oncology, Inc. Récepteurs antigéniques chimériques contre axl ou ror2 et procédés d'utilisation associés
US20190010220A1 (en) * 2014-08-28 2019-01-10 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2331566B1 (fr) * 2008-08-26 2015-10-07 City of Hope Procédé et compositions pour fonctionnement amélioré d'effecteur antitumoral de lymphocytes t
US20130280220A1 (en) * 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
DK2956175T3 (da) * 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
WO2016036916A1 (fr) * 2014-09-03 2016-03-10 Bioatla, Llc Découverte et production de protéines biologiques conditionnellement actives dans les mêmes cellules hôtes eucaryotes de production
SMT202600033T1 (it) 2016-04-15 2026-03-09 Bioatla Inc Anticorpi anti-axl, frammenti di anticorpo e loro immunoconiugati e loro utilizzi
AU2017320874B2 (en) 2016-08-31 2024-03-07 Bioatla, Llc Conditionally active polypeptides and methods of generating them

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016033331A1 (fr) * 2014-08-28 2016-03-03 Bioatla, Llc Récepteurs d'antigènes chimères conditionnellement actifs pour cellules t modifiées
US20190010220A1 (en) * 2014-08-28 2019-01-10 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
WO2018136570A1 (fr) * 2017-01-18 2018-07-26 F1 Oncology, Inc. Récepteurs antigéniques chimériques contre axl ou ror2 et procédés d'utilisation associés

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHO JANG HWAN ET AL: "Engineering Axl specific CAR and SynNotch receptor for cancer therapy", SCIENTIFIC REPORTS, vol. 8, no. 1, 1 March 2018 (2018-03-01), pages 3846, XP055916559, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-018-22252-6.pdf> DOI: 10.1038/s41598-018-22252-6 *
NERRETER T ET AL: "ROR2 is a novel target for CAR T cells in breast cancer", ONCOLOGY RESEARCH AND TREATMENT20170901S. KARGER AGNLD, vol. 40, no. 3, 1 September 2017 (2017-09-01), Oncology Research and Treatment20170901S. Karger AGnld, pages 130, XP055916567, ISSN: 2296-5262 *
WEI JING ET AL: "A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers", CELLULAR IMMUNOLOGY, vol. 331, 1 September 2018 (2018-09-01), US, pages 49 - 58, XP055879132, ISSN: 0008-8749, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0008874918301618/pdfft?md5=49bb4e1e019ba14d9de246f49a3be59d&pid=1-s2.0-S0008874918301618-main.pdf> DOI: 10.1016/j.cellimm.2018.05.004 *

Also Published As

Publication number Publication date
JP2021536256A (ja) 2021-12-27
AU2019334864A1 (en) 2021-03-11
TW202024124A (zh) 2020-07-01
AU2019334864B2 (en) 2025-11-20
WO2020050993A3 (fr) 2020-04-16
CN112823166B (zh) 2025-01-24
WO2020050993A2 (fr) 2020-03-12
TWI835848B (zh) 2024-03-21
JP7432250B2 (ja) 2024-02-16
EP3847191A2 (fr) 2021-07-14
CN112823166A (zh) 2021-05-18

Similar Documents

Publication Publication Date Title
EP3924799A4 (fr) Géorepères pour navigation d&#39;uav
EP3848387A4 (fr) Récepteur antigénique chimérique pour un cancer solide et lymphocytes t exprimant ce récepteur chimérique de l&#39;antigène
MA53330A (fr) Constructions d&#39;anticorps pour cldn18.2 et cd3
EP3791569A4 (fr) Structure d&#39;anneau de caméra pour véhicules autonomes
EP3815398A4 (fr) Modèle d&#39;ensemble de multi-synchronisation pour localisation de dispositif
EP3867724A4 (fr) Priorisation d&#39;agents pour véhicules autonomes
EP3782090A4 (fr) Auto-achèvement contextuel pour systèmes d&#39;assistance
EP3635099A4 (fr) Lymphocytes t exprimant un récepteur d&#39;antigène chimérique
EP3870555A4 (fr) Station d&#39;accueil pour robot nettoyeur
EP3740217A4 (fr) Procédés d&#39;utilisation pour des lymphocytes t car
EP3752170A4 (fr) Récepteurs d&#39;antigènes chimériques ciblant le micro-environnement
MA49990A (fr) Récepteurs de liaison à l&#39;antigène améliorés
MA51043A (fr) Récepteurs de lymphocytes t, limités à l&#39;antigène hla de classe i, ayant une spécificité antigénique pour toute protéine ras mutée
EP3440191A4 (fr) Compositions de lymphocytes t récepteurs d&#39;antigènes chimériques
EP3847191A4 (fr) Récepteurs d&#39;antigènes chimériques conditionnellement actifs pour lymphocytes t modifiés
EP3470424A4 (fr) Séquence de région constante à chaîne lourde d&#39;anticorps pour améliorer l&#39;activité d&#39;anticorps agonistes
EP3999079A4 (fr) Polypeptide de fusion pour l&#39;immunothérapie
EP3860977A4 (fr) Antagonistes de l&#39;intégrine
EP3694872A4 (fr) Compositions de lymphocytes t pour l&#39;immunothérapie
EP3963462A4 (fr) Architectures efficaces pour algorithmes d&#39;apprentissage profond
EP3959112A4 (fr) Détection d&#39;objets disparus pour véhicules autonomes
EP3402518A4 (fr) Anticorps de type récepteurs des lymphocytes t spécifiques pour des peptides dérivés de foxp3
EP3880710A4 (fr) Anticorps anti-cd73 activant les lymphocytes b
EP4069351A4 (fr) Détection d&#39;objet saillant pour vision artificielle
EP3990495A4 (fr) Anticorps pour l&#39;activation de lymphocytes t

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210322

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0016180000

Ipc: C07K0016280000

A4 Supplementary search report drawn up and despatched

Effective date: 20220510

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20220503BHEP

Ipc: C07K 14/735 20060101ALI20220503BHEP

Ipc: A61K 35/17 20150101ALI20220503BHEP

Ipc: C07K 14/705 20060101ALI20220503BHEP

Ipc: A61K 39/395 20060101ALI20220503BHEP

Ipc: C07K 14/725 20060101ALI20220503BHEP

Ipc: C07K 16/28 20060101AFI20220503BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221210